2024/11/01 07:00:00 | |
---|---|
Price | |
4,270.00 JPY | |
Difference | 0.14% (6.00) |
ISIN | JP3463000004 |
Symbol | 4502 |
Exchange | Tokyo Stock Exchange |
Currency | JPY |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 40,610 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | 4,265.00 JPY (300) |
Ask (Ask size) | 4,270.00 JPY (8,400) |
Open | 4,194.00 JPY |
High | 4,313.00 JPY |
Low | 4,194.00 JPY |
Close (prev. day) | 4,264.00 JPY |
VWAP | 4,274.0553 JPY |
Volume (pcs) | 5,114,600 |
Trading volume | 218,600,831.00 |
Number of trades | 6,824 |
Last size | 1,028,500 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/10/29 | Global Equity Ratings | ||
2024/10/29 | Aktienempfehlungen Global | ||
2024/10/22 | Global Equity Ratings | ||
2024/10/22 | Aktienempfehlungen Global | ||
2024/10/14 | Aktienempfehlungen Österreich |
2024/11/01 07:00:00 | |
---|---|
Price | |
4,270.00 JPY | |
Difference | 0.14% (6.00) |
ISIN | JP3463000004 |
Symbol | 4502 |
Exchange | Tokyo Stock Exchange |
Currency | JPY |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 40,610 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | 4,265.00 JPY (300) |
Ask (Ask size) | 4,270.00 JPY (8,400) |
Open | 4,194.00 JPY |
High | 4,313.00 JPY |
Low | 4,194.00 JPY |
Close (prev. day) | 4,264.00 JPY |
VWAP | 4,274.0553 JPY |
Volume (pcs) | 5,114,600 |
Trading volume | 218,600,831.00 |
Number of trades | 6,824 |
Last size | 1,028,500 |
6M | 1Y | 3Y | |
Perf (%) | +3.07% | +3.57% | +31.30% |
Perf (abs.) | +127.00 | +147.00 | +1,018.00 |
Beta | 0.33 | 0.33 | 0.41 |
Volatility | 20.73 | 18.41 | 18.10 |
Ø price 5 days | Ø volume 5 days (pcs.) | 4,230.80 JPY (4,614,100) |
Ø price 30 days | Ø volume 30 days (pcs.) | 4,223.47 JPY (4,073,113) |
Ø price 100 days | Ø volume 100 days (pcs.) | 4,223.19 JPY (4,045,958) |
Ø price 250 days | Ø volume 250 days (pcs.) | 4,213.19 JPY (4,197,394) |
YTD High | date | 4,494.00 JPY (2024/02/27) |
YTD Low | date | 3,852.00 JPY (2024/08/06) |
52 Weeks High | date | 4,494.00 JPY (2024/02/27) |
52 Weeks Low | date | 3,852.00 JPY (2024/08/06) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Vienna Stock Exchange | 2024/11/01 | 11:00 | 25.69 EUR | 0.00 | 2 |
Tradegate | 2024/11/01 | 12:06 | 25.76 EUR | 0.01 | 5 |
Tokyo Stock Exchange | 2024/11/01 | 07:00 | 4,270.00 JPY | 218.60 | 6,824 |
Stuttgart | 2024/11/01 | 08:13 | 25.57 EUR | 0.00 | 1 |
Sapporo Stock Exchange | 2024/10/23 | 03:22 | 4,185.00 JPY | 0.01 | 1 |
Munich | 2024/11/01 | 08:03 | 25.67 EUR | 0.00 | 1 |
London Stock Exchange | 2019/03/26 | 12:28 | 37.59 EUR | 0.00 | 1 |
Hanover | 2024/11/01 | 08:01 | 25.47 EUR | 0.00 | 1 |
Hamburg | 2024/11/01 | 08:01 | 25.67 EUR | 0.00 | 1 |
Fukuoka Stock Exchange | 2024/04/17 | 02:25 | 4,080.00 JPY | 0.00 | 1 |
Frankfurt | 2024/11/01 | 09:06 | 25.68 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/10/31 | 15:51 | 27.00 USD | 0.01 | 5 |
Duesseldorf | 2024/11/01 | 09:31 | 25.56 EUR | 0.00 | 2 |
Berlin | 2024/11/01 | 08:08 | 25.66 EUR | 0.00 | 1 |
TAKEDA PHARMACEUTICAL CO. LTD. |
- - |
4-1-1 Dosho-machi, Chuo-Ku - 540-8645 Osaka |
Telefon: +81-6-6204-2111 |
Fax: +81-6-6204-2880 |
E-mail: - |
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan. |
Christophe Weber | Chairman of Managing Board |
Andrew Plump | Member of Executive Committee |
Costa Saroukos | Member of Executive Committee |
Gabriele Ricci | Member of Executive Committee |
Giles Platford | Member of Executive Committee |
Julie Kim | Member of Executive Committee |
Koki Sato | Member of Executive Committee |
Lauren Duprey | Member of Executive Committee |
Marcello Agosti | Member of Executive Committee |
Milano Furuta | Member of Executive Committee |
Mwana Lugogo | Member of Executive Committee |
Ramona Sequeira | Member of Executive Committee |
Takako Ohyabu | Member of Executive Committee |
Teresa Bitetti | Member of Executive Committee |
Thomas Wozniewski | Member of Executive Committee |
Yoshihiro Nakagawa | Member of Executive Committee |
Masami Iijima | Chairman of Supervisory Board |
Andrew Plump | Member of Supervisory Board |
John Maraganore | Member of Supervisory Board |
Steven Gillis | Member of Supervisory Board |
Emiko Higashi | Member of Supervisory Board |
Ian Clark | Member of Supervisory Board |
Jean-Luc Butel | Member of Supervisory Board |
Kimberly Reed | Member of Supervisory Board |
Koji Hatsukawa | Member of Supervisory Board |
Michel Orsinger | Member of Supervisory Board |
Miki Tsusaka | Member of Supervisory Board |
Milano Furuta | Member of Supervisory Board |
Yoshiaki Fujimori | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.